• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>ACP Journal Club >Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin
【24h】

Oral vitamin K did not reduce bleeding in patients with excessive anticoagulation after receiving warfarin

机译：口服华法林后，口服维生素K并不能减少抗凝药过多的患者的出血

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

QuestionnnIn patients with warfarin-associated coagulopathy, does low-dose oral vitamin K reduce risk for bleeding?nnMethodsnnDesign: Randomized placebo-controlled trial. ClinicalTrials.gov NCT00143715.nnAllocation: Concealed.*nnBlinding: Blinded (patients, clinicians, research coordinators, and outcome adjudicators).*nnFollow-up period: 90 days.nnSetting: 14 anticoagulant centers in the USA, Canada, and Italy.nnPatients: 724 outpatients 18 years of age (mean age 69 y, 53% men) who attended clinic for routine international normalized ratio (INR) assessment, were receiving warfarin with a target INR of 2.0 to 3.5, were not bleeding, and had an INR between 4.5 and 10.0 in the past 24 hours. Exclusion criteria included life expectancy < 10 days, indication for acute normalization of INR, scheduled discontinuation of warfarin, known bleeding disorder, recent major bleeding, inability to take oral medication or undergo follow-up, contraindication to vitamin K, severe liver disease, thrombolytic therapy within 48 hours, and platelet count < 50 x 109 cells/L.nnIntervention: Single-dose oral vitamin K, 1.25 mg (n = 355), or placebo (n = 369).nnOutcomes: Any bleeding events at 90 days. Secondary outcomes included major bleeding (fatal bleeding, bleeding requiring transfusion of 2 units of packed red blood cells or therapeutic intervention, or objectively confirmed bleeding into an enclosed space), objectively confirmed venous or arterial thromboembolism, and death.nnPatient follow-up: 98% (100% in intention-to-treat analysis).
机译：在华法林相关性凝血病患者中，低剂量口服维生素K是否可降低出血风险？nn方法设计：随机安慰剂对照试验。 ClinicalTrials.gov NCT00143715.nn分配：隐藏。* nn盲：盲人（患者，临床医生，研究协调员和结果判断者）。* nn随访时间：90天。nn设置：美国，加拿大和意大利的14个抗凝中心。 ：724名18岁（平均年龄69岁，男性占53％）的门诊病人就诊，接受常规国际标准化比率（INR）评估，接受华法林的目标INR为2.0至3.5，不出血，并且具有INR在过去24小时内处于4.5和10.0之间。排除标准包括预期寿命<10天，INR急性恢复正常，华法林计划停药，已知出血性疾病，近期大出血，不能口服药物或无法随访，维生素K禁忌症，严重肝病，溶栓48小时内接受治疗，血小板计数<50 x 109个细胞/升.nn干预：单剂量口服维生素K，1.25毫克（n = 355）或安慰剂（n = 369）.nn结果：90天时发生任何出血事件。次要结果包括严重出血（致命性出血，需要输注2个单位堆积红细胞或治疗性干预的出血，或客观确诊的出血进入密闭空间），客观确诊的静脉或动脉血栓栓塞和死亡.nn患者的随访情况：98 ％（意向性分析中为100％）。

著录项

  • 来源
    《ACP Journal Club》 |2009年第6期|p.9-9|共1页
  • 作者

    Matthew Rondina MD;

  • 作者单位

    University of UtahSalt Lake City, Utah, USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号